阿斯利康攜四項重要研究首發(fā)數(shù)據(jù)亮相歐洲腫瘤內(nèi)科學會（ESMO）年會，進一步彰顯重新定義癌癥治療的雄心

阿斯利康

2025-10-14 21:00 4194

DESTINY-Breast11與DESTINY-Breast05兩項研究入選主席研討會（Presidential Symposium），凸顯德曲妥珠單抗在治療HER2陽性早期乳腺癌中的潛在價值

TROPION-Breast02研究數(shù)據(jù)將展示德達博妥單抗在轉(zhuǎn)移性三陰性乳腺癌這一最具侵襲性的乳腺癌分型中的治療潛力

POTOMAC研究的無病生存期數(shù)據(jù)與MATTERHORN研究的生存期數(shù)據(jù)將展示度伐利尤單抗在早期膀胱癌與胃癌治療中的獲益

上海2025年10月14日 /美通社/ -- 阿斯利康將于2025年10月17日至21日召開的歐洲腫瘤內(nèi)科學會（ESMO）年會上，憑借?業(yè)領(lǐng)先的多樣化產(chǎn)品與管線布局的全新研究數(shù)據(jù)，進一步彰顯其重新定義癌癥治療格局的雄心壯志。

本次大會上，阿斯利康將公布逾95項摘要，涵蓋9款已獲得批準藥物及9款潛在新藥，包括2項入選重要主席研討會（Presidential Symposium）的摘要以及26項口頭報告。

其中主要亮點包括：

DESTINY-Breast11：評估德曲妥珠單抗序貫THP方案（紫杉醇、曲妥珠單抗及帕妥珠單抗）用于高風險HER2陽性早期乳腺癌新輔助治療的III期臨床研究（主席研討會1，摘要#291O）。
DESTINY-Breast05：評估德曲妥珠單抗用于HER2陽性早期乳腺癌（新輔助治療后存在殘留浸潤病灶并具有高復發(fā)風險）的III期臨床研究（主席研討會1，摘要#LBA1）。
TROPION-Breast02：評估德達博妥單抗用于一線治療無法接受免疫治療的局部復發(fā)性不可手術(shù)或轉(zhuǎn)移性三陰性乳腺癌（TNBC）患者的III期臨床研究（優(yōu)選論文摘要#LBA21）。
POTOMAC：評估度伐利尤單抗聯(lián)合卡介苗（BCG）誘導與維持治療，用于高危非肌層浸潤性膀胱癌（NMIBC）患者的III期臨床研究（優(yōu)選論文摘要#LBA108）。
MATTERHORN：公布III期臨床研究的最終總生存期（OS）結(jié)果，評估度伐利尤單抗聯(lián)合FLOT化療作為可切除的早期和局部晚期的胃和胃?管結(jié)合部腺癌（GEJ）患者圍手術(shù)期治療中的臨床獲益（優(yōu)選論文摘要#LBA81）。

阿斯利康全球執(zhí)行副總裁、全球腫瘤研發(fā)負責人高書璨（Susan Galbraith）表示："我們正加速推進多元創(chuàng)新療法管線，以變革乳腺癌患者的治療格局。在本屆ESMO大會上，我們將公布TROPION-Breast02、DESTINY-Breast11和DESTINY-Breast05研究的數(shù)據(jù)和重要進展。同時，我們也將展示新一代潛在抗腫瘤新藥的數(shù)據(jù)，包括saruparib聯(lián)合新型激素療法用于前列腺癌領(lǐng)域，靶向葉酸受體的抗體偶聯(lián)藥物torvu-sam用于卵巢癌領(lǐng)域，以及rilvegostomig用于在非小細胞肺癌領(lǐng)域。"

阿斯利康全球執(zhí)行副總裁，腫瘤業(yè)務負責人Dave Fredrickson表示："我們業(yè)界領(lǐng)先的腫瘤產(chǎn)品組合在本次ESMO持續(xù)展現(xiàn)強勁勢頭，首次公布了四項關(guān)鍵研究的數(shù)據(jù)。其中，不僅有德曲妥珠單抗和德達博妥單抗在乳腺癌領(lǐng)域的重大進展，度伐利尤單抗的POTOMAC試驗結(jié)果也證明了免疫療法為早期膀胱癌治療帶來的益處，進而闡釋我們的策略——將前沿治療引入癌癥早期這一患者最能夠獲益的階段。"

其他亮點包括：

FONTANA：評估靶向葉酸受體α（FRα）的抗體藥物偶聯(lián)物AZD5335用于鉑耐藥復發(fā)性卵巢癌患者的I/IIa期首次人體臨床試驗（簡短口頭報告摘要#1065MO）。
PETRANHA：評估saruparib聯(lián)合雄激素受體通路抑制劑用于治療轉(zhuǎn)移性前列腺癌患者的I/II期臨床研究（簡短口頭報告摘要#2384MO）。
ARTEMIDE-01：評估rilvegostomig用于檢查點抑制劑初治的轉(zhuǎn)移性非小細胞肺癌（NSCLC）患者的I/II期臨床研究（簡短口頭報告摘要#1853MO）。
FLAURA2：在奧希替尼合化療治療晚期EGFR突變NSCLC患者的FLAURA2 III期臨床研究中存在不良預后因素患者的探索性O(shè)S分析（優(yōu)選論文摘要#LBA77）。
CAPItello-281：卡匹色替聯(lián)合阿比特龍和雄激素剝奪療法（ADT）用于PTEN缺陷的新發(fā)轉(zhuǎn)移性激素敏感性前列腺癌（mHSPC）的III期臨床研究（優(yōu)選論文摘要#2383O）。
TROPION-PanTumor03：評估德達博妥單抗聯(lián)合rilvegostomig治療局晚期或轉(zhuǎn)移性尿路上皮癌（a/mUC）患者的療效： II期TROPION-PanTumor03研究結(jié)果結(jié)果（簡短口頭報告摘要 #3072MO）
BEGONIA：德達博妥單抗聯(lián)合度伐利尤單抗用于既往未經(jīng)治療的不可切除、局部晚期或轉(zhuǎn)移性三陰性乳腺癌（TNBC）患者的BEGONIA Ib/II期試驗最終結(jié)果（口頭報告摘要#555MO）。

阿斯利康與第?三共聯(lián)合開發(fā)和商業(yè)化德曲妥珠單抗與德達博妥單抗；與默沙東（默沙東是美國新澤西州羅威市默克公司的公司商號）聯(lián)合開發(fā)和商業(yè)化奧拉帕利；與和黃醫(yī)藥合作開發(fā)和商業(yè)化賽沃替尼。Rilvegostomig是一種靶向PD-1和TIGIT的雙特異性抗體，其中TIGIT部分源自Compugen公司臨床階段的抗TIGIT抗體COM902。

阿斯利康在2025年ESMO年會期間的重要演講^[1]

主要作者	摘要標題	報告詳情(CEST)
抗體偶聯(lián)藥物
Harbeck, N	DESTINY-Breast11: neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC)	Abstract #291O Presidential 1 18 October 2025 4:30 PM
Geyer, C	Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05	Abstract #LBA1 Presidential 1 18 October 2025 4:52 PM
Dent, R.	First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase 3 TROPION-Breast02 trial	Abstract #LBA21 Proffered Paper Session 19 October 2025 9:25 AM
Loibl, S	Trastuzumab deruxtecan (T-DXd) + pertuzumab vs taxane + trastuzumab + pertuzumab (THP) for patients with HER2+ advanced/metastatic breast cancer: additional analysis of DESTINY-Breast09 in key subgroups of interest	Abstract #LBA18 Proffered Paper Session 19 October 2025 8:30 AM
Rha, SY	Datopotamab deruxtecan (Dato-DXd) + rilvegostomig (rilve) in patients (pts) with locally advanced or metastatic urothelial cancer (a/mUC): Results from the phase 2 TROPION-PanTumor03 study	Abstract #3072MO Mini Oral Session 17 October 2025 4:10 PM
Oaknin, A	First-in-human study of AZD5335, a folate receptor α (FRα)-targeted antibody-drug conjugate, in patients with platinum-resistant recurrent ovarian cancer	Abstract #1065MO Mini Oral Session 19 October 2025 10:53 AM
Schmid, P	Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment (tx) for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Final results from the phase 1b/2 BEGONIA study	Abstract #555MO Mini Oral Session 20 October 2025 10:50 AM
Raghav, K	Trastuzumab deruxtecan (T DXd) in patients (pts) with HER2-positive (HER2+) metastatic colorectal cancer (mCRC): Final analysis of DESTINY-CRC02, a randomized, phase 2 trial	Abstract #737P Poster Session
Peng, Z	Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA) who received prior anti-HER2 treatment (Tx) other than / in addition to trastuzumab in DESTINY-Gastric06 (DG-06)	Abstract #2105P Poster Session
Shen, L	Risk of hepatitis B virus reactivation (HBVr) in patients (pts) with past or resolved HBV or inactive chronic HBV infection treated with trastuzumab deruxtecan (T-DXd) in the DESTINY-Gastric06 (DG-06) trial	Abstract #2175P Poster Session
Pietrantonio, F	Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) plus paclitaxel (PTX) in second-line (2L) treatment of patients (pts) with HER2+ unresectable/metastatic gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Additional data from DESTINY-Gastric04 (DG-04)	Abstract #2099P Poster Session
Makker, V	Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: DESTINY- PanTumor02 (DP-02) Part 1 final analysis	Abstract #957P Poster Session
Lee, J-Y	Trastuzumab deruxtecan (T-DXd) in pretreated patients (pts) with HER2-expressing solid tumors: exploratory biomarker analysis of DESTINY-PanTumor02 (DP-02) Part 1	Abstract #145P Poster Session
免疫腫瘤學
Tabernero, J	MATTERHORN Phase III trial of Imfinzi (durvalumab) perioperative Imfinzi (durvalumab) plus FLOT chemotherapy in patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction (GEJ) cancers	Abstract #LBA81 Proffered Paper Session 17 October 2025 2:00 PM
De Santis, M	Durvalumab (D) in Combination with Bacillus Calmette- Guérin (BCG) for BCG-naïve, High-risk Non-muscle- invasive Bladder Cancer (NMIBC): Results from the Phase 3, Open-label, Randomised POTOMAC Trial	Abstract #LBA108 Proffered Paper Session 17 October 2025 2:10 PM
Larkin, J	First results from RAMPART: An international phase 3 randomised-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) led by MRC CTU at UCL	Abstract #LBA93 Proffered Paper Session 18 October 2025 9:20 AM
Aghajanian, C	Durvalumab + paclitaxel/carboplatin + bevacizumab followed by durvalumab, bevacizumab + olaparib maintenance in patients with newly diagnosed non-tBRCA- mutated advanced ovarian cancer: final overall survival from DUO-O/ENGOT-ov46/GOG-3025	Abstract #LBA44 Mini Oral Session 19 October 2025 11:31 AM
Goss, G	CCTG BR.31: Adjuvant durvalumab (D) in resected non- small-cell lung cancer (NSCLC): final overall survival (OS) and minimal residual disease (MRD) analyses	Abstract #LBA68 Mini Oral Session 20 October 2025 3:20 PM
Heymach, J	Association of radiomic features ± on-treatment ctDNA detection with treatment outcomes in patients with resectable NSCLC: exploratory analyses from AEGEAN	Abstract #LBA70 Mini Oral Session 20 October 2025 3:50 PM
Wermke, M	Tarlatamab with first-line chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC): DeLLphi-303 study	Abstract #2757O Proffered Paper Session 18 October 2025 8:30 AM
Loibl, S	Durvalumab in Combination with Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC) – Long-term Analysis from the GeparNuevo Trial	Abstract #292MO Mini Oral Session 19 October 2025 10:15 AM
Van der Heijden, M	Health-related quality of life (HRQoL) from the NIAGARA trial of perioperative durvalumab (D) plus neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC)	Abstract #3069MO Mini Oral Session 17 October 2025 4:00 PM
Sangro, B	Pooled efficacy and safety outcomes with tremelimumab plus durvalumab in participants (pts) with unresectable hepatocellular carcinoma (uHCC) from the combined China extension and global cohorts in the Phase 3 HIMALAYA study	Abstract #1494P Poster Session
Westin, S	Durvalumab plus carboplatin/paclitaxel followed by durvalumab for endometrial cancer: Tumour mutational burden-high subpopulation efficacy analyses from the DUO-E trial	Abstract #1117P Poster Session
Leal, TA	Global quantitative assessment of multidisciplinary team (MDT) care in early-stage NSCLC	Abstract #1794P Poster Session
Reck, M	Neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery (Sx) and adjuvant D or CRT and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC: interim analysis (IA) of the phase 2 MDT-BRIDGE study	Abstract #LBA65 Proffered Paper Session 18 October 2025 9:15 AM
Maruki, Y	CELEBRATE Study (JCOG2107E): A Multicenter, Open- label, Phase III Trial of Etoposide, Carboplatin, and Durvalumab in First-line Treatment of Unresectable or Recurrent Digestive NEC	Abstract #1734TiP Poster Session
Oudard, S	A phase IIIb, open-label, single-arm, global study of perioperative durvalumab (D) with neoadjuvant dose- dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) or gemcitabine/cisplatin (gem/cis) in patients with muscle-invasive bladder cancer (MIBC) (NIAGARA-2)	Abstract #3133eTiP ePoster Session
雙特異性抗體
Chul Cho, B	Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT Bispecific Antibody, for Checkpoint Inhibitor (CPI)-Naïve Metastatic Non-Small-Cell Lung Cancer (mNSCLC): ARTEMIDE-01	Abstract #1853MO Mini Oral Session 20 October 2025 10:25 AM
Slomovitz, BM	A randomized Phase 3 study of first-line (1L) trastuzumab deruxtecan (T-DXd) with rilvegostomig or pembrolizumab in patients with HER2-expressing, mismatch repair- proficient (pMMR), primary advanced or recurrent endometrial cancer (EC): DESTINY-Endometrial01/GOG- 3098/ENGOT-EN24	Abstract #1223TiP Poster Session
Naidoo, J	ARTEMIDE-Lung04: A Phase 3, randomised, double-blind, global study of rilvegostomig or pembrolizumab monotherapy as first-line (1L) treatment for patients with metastatic non-small cell lung cancer (mNSCLC) and programmed cell death ligand-1 (PD-L1) expression ≥50%	Abstract #2025TiP Poster Session
腫瘤驅(qū)動因子和耐藥性
Jänne, PA	FLAURA2: exploratory overall survival (OS) analysis in patients (pts) with poor prognostic factors treated with osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) as first-line (1L) treatment for EGFR-mutated (EGFRm) advanced NSCLC	Abstract #LBA77 Proffered Paper Session 17 October 2025 4:56 PM
Mayer, E	Patient-reported outcomes (PROs) from the SERENA-6 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1m during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2- advanced breast cancer (ABC)	Abstract #486MO Mini Oral Session 20 October 2025 10:25 AM
Arriola, E	Molecular residual disease (MRD) analysis from the LAURA study of osimertinib (osi) in unresectable (UR) stage III EGFR-mutated (EGFRm) NSCLC	Abstract #1817MO Mini Oral Session 20 October 2025 2:55 PM
Park, YH	Visual symptom questionnaire results from SERENA-6, a Phase 3 study of switch to camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) at emergence of ESR1m during first- line (1L) therapy for patients (pts) with HR+/HER2- advanced breast cancer (ABC)	Abstract #528P Poster Session
Chu, Q	SAVANNAH: Safety and tolerability of osimertinib (osi) + savolitinib (savo) in EGFRm advanced NSCLC with MET overexpression and/or amplification (OverExp/Amp) following disease progression on osi	Abstract #1955P Poster Session
Rotow, J	MET testing and treatment (tx) sequencing after progression on first line (1L) osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and acquired MET overexpression and/or amplification (OverExp/Amp): Interim analysis of a global real world (rw) study	Abstract #1967P Poster Session
Yu, Y	ctDNA analysis in phase 3 SACHI trial: Savolitinib (savo) plus osimertinib (osi) versus chemotherapy (chemo) in MET-amplified (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI)	Abstract #1954P Poster Session
DNA損傷應答
Azad, AA	First interim efficacy analysis of the Phase 1/2 PETRANHA trial of saruparib + androgen receptor pathway inhibitors (ARPI) in patients (pts) with metastatic prostate cancer (mPC)	Abstract #2384MO Mini Oral Session 17 October 2025 2:35 PM
Fizazi, K	A Phase 3 study of capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281	Abstract #2383O Proffered Paper Session 19 October 2025 11:19 AM
Rugo, HS	Capivasertib with fulvestrant as first- and second-line endocrine therapy in PIK3CA/AKT1/PTEN-altered hormone receptor-positive advanced breast cancer: Subgroup analysis from the Phase 3 CAPItello-291 trial	Abstract #526P Poster Session
Gao, Q	Final overall survival (OS) analysis of L-MOCA: olaparib maintenance monotherapy in patients (pts) with platinum- sensitive relapsed ovarian cancer (PSR OC)	Abstract #1090P Poster Session
AI驅(qū)動的臨床試驗
Gonuguntla, HK	Real-World Validation of AI-defined Lung Nodule Malignancy Score (qXR-LNMS) in Predicting Risk of Lung Cancer: Interim results from Phase 2	Abstract #2978P Poster Session

^[1]阿斯利康在2025年ESMO年會將公布逾90個摘要，涵蓋其產(chǎn)品和管線中的分子藥物

關(guān)于阿斯利康腫瘤領(lǐng)域的研究

阿斯利康正引領(lǐng)著腫瘤領(lǐng)域的?場革命，致力提供多元化的腫瘤治療方案，以科學探索腫瘤領(lǐng)域的復雜性，發(fā)現(xiàn)、研發(fā)并向患者提供改變生命的藥物。

阿斯利康專注于最具挑戰(zhàn)性的腫瘤疾病，通過持續(xù)不斷的創(chuàng)新，阿斯利康已經(jīng)建立了行業(yè)領(lǐng)先的多元化的產(chǎn)品組合和管線，持續(xù)推動醫(yī)療實踐變?，改變患者體驗。

阿斯利康以期重新定義癌癥治療并在未來攻克癌癥。

關(guān)于阿斯利康

阿斯利康（LSE/STO/Nasdaq: AZN）是?家科學至上的全球生物制藥企業(yè)，專注于研發(fā)、生產(chǎn)及營銷處方類藥品，重點關(guān)注腫瘤、罕見病以及包括心血管腎臟及代謝、呼吸及免疫在內(nèi)的生物制藥等領(lǐng)域。阿斯利康全球總部位于英國劍橋，業(yè)務遍布超過125個國家，創(chuàng)新藥物惠及全球數(shù)百萬患者。更多信息，請訪問www.astrazeneca.com。

關(guān)于阿斯利康中國

阿斯利康自1993年進入中國以來，專注中國患者需求最迫切的治療領(lǐng)域，包括腫瘤、心血管、腎臟、代謝、呼吸、消化、罕見病、疫苗抗體及自體免疫等，已將40多款創(chuàng)新藥物帶到中國。阿斯利康中國總部位于上海，并在上海和北京設(shè)立全球戰(zhàn)略研發(fā)中心，在北京、廣州、杭州、成都、青島設(shè)立區(qū)域總部，在無錫、泰州、青島建立全球生產(chǎn)供應基地，向全球70多個市場輸送優(yōu)質(zhì)創(chuàng)新藥品。

聲明：本文研究中涉及的多種藥品用法尚未在中國獲批適應癥，阿斯利康不推薦任何未被批準的藥品使用。

消息來源：阿斯利康

相關(guān)股票：

LSE:AZN NASDAQ:AZN Stockholm:AZN